79.02 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||62.00 x 900|
|Ask||79.02 x 800|
|Day's range||78.15 - 82.55|
|52-week range||41.67 - 84.23|
|PE ratio (TTM)||N/A|
|Earnings date||25 Jul 2018 - 30 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||68.05|
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that the Phase 3 study of Crysvita® (burosumab) met its primary endpoint demonstrating that Crysvita was superior to oral phosphate and active vitamin D (conventional therapy) in improving rickets in children with X-linked hypophosphatemia (XLH) after 40 weeks of treatment (LS Mean treatment difference of +1.14, p
The Novato, California-based company said it had profit of 62 cents per share. The results beat Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for ...
Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) today announce that Crysvita (burosumab) has received a positive European Commission decision granting a conditional marketing authorisation to Kyowa Kirin for the treatment of X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. XLH is a rare, chronic progressive musculoskeletal disorder that affects children and adults.
On a per-share basis, the Novato, California-based company said it had a loss of $1.89. Losses, adjusted for pretax gains, came to $2.27 per share. The results fell short of Wall Street expectations. The ...
Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the appointment of John Hohneker, M.D., as president and chief executive officer, effective January 22. Dr. Hohneker joins Anokion from FORMA Therapeutics Inc., where he served as president of research and development. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, most recently as senior vice president and global head of development for immunology and dermatology.
Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
Ultragenyx popped to a seven-week high Monday on data from a Phase 3 trial for a drug to treat a rare bone disease.
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
The Novato, California-based company said it had a loss of $1.87 per share. The results matched Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was also ...
Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.
Spark's positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx.